Drug Trial Radar · NCT04227483
Deflazacort Vs. Prednisolone in Acute-stage ABPA
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Actual
Start
Jan 15, 2020
Primary completion
Jul 2025
Study completion Jul 2025
Sponsor
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Oral glucocorticoids are currently the treatment of choice for allergic bronchopulmonary aspergillosis (ABPA). They not only suppress the immune hyperfunction but are also anti-inflammatory. Unfortunately, numerous toxicities and adverse effects have been attributed to glucocorticoids related to both the average dose and cumulative duration of use. Deflazacort is a oxazoline steroid with demonstrated anti-inflammatory and immunosuppressant effects. The novel structural characteristic of deflazacort is associated with substantial lack of sodium-retaining activity, lower interference with carbohydrate metabolism and calcium metabolism in comparison with older glucocorticoids such as prednisolone. The investigators hypothesize that the occurrence of side-effects, primarily weight gain will be lower with deflazacort. In this study, the investigators will compare the safety and efficacy of deflazacort in the treatment of acute-stage ABPA complicating asthma.
Conditions
- Allergic Bronchopulmonary Aspergillosis
Interventions
DeflazacortDrug
Deflazacort for 4 months
PrednisoloneDrug
Prednisolone for 4 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Weight gainTime frame: 2 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chest Clinic, Dept. of Pulmonary Medicine
Chandigarh, Chandigarh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.